{"id":2293,"date":"2025-01-06T22:27:11","date_gmt":"2025-01-06T19:27:11","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2293"},"modified":"2025-03-07T15:29:39","modified_gmt":"2025-03-07T12:29:39","slug":"percheron-disappointed-in-avicursen-atl1102-study-for-duchenne-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/percheron-disappointed-in-avicursen-atl1102-study-for-duchenne-dmd\/","title":{"rendered":"Percheron decepcionado con el estudio de Avicursen (ATL1102) para Duchenne (DMD)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a letter to shareholders published today (6 January), the chair of the board Dr Charmaine Gittleson, alongside non-executive director Dr Gil Price and managing director Dr James Garner, told shareholders that the company \u201cwill undertake a broad strategic review of the company\u2019s pipeline to more comprehensively evaluate alternative sources of value within the current assets\u201d.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The review follows negative topline results from the Phase IIb trial (NCT05938023) of avicursen in boys with non-ambulatory DMD. Announced on 18 December, the results demonstrated that the trial did not meet its primary endpoint, which was the Performance of the Upper Limb 2.0 (PUL2.0) score at week 25 compared to placebo. [<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05938023\" target=\"_blank\" rel=\"noreferrer noopener\">Learn More about Clinical Trial<\/a>]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.clinicaltrialsarena.com\/news\/percheron-plans-to-broaden-pipeline-following-avicursen-disappointment\/\" target=\"_blank\" rel=\"noreferrer noopener\">Read More<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month. In a letter to shareholders published today (6 January), the chair of the board Dr Charmaine Gittleson, alongside non-executive director Dr Gil Price and managing director Dr James Garner, told [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2295,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[114,113,117,118,66,116,112,115],"class_list":["post-2293","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-atl1102","tag-avicursen","tag-dmd","tag-duchenne","tag-duchenne-muscular-dystrophy","tag-nct05938023","tag-percheron","tag-percheron-therapeutics"],"subtitle":"Percheron planea ampliar su cartera de productos tras la decepci\u00f3n de Avicursen (ATL1102). Tras los decepcionantes resultados de la fase IIb de Avicursen el mes pasado, Percheron adoptar\u00e1 una estrategia comercial de tres frentes.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=2293"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2293\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/2295"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=2293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=2293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=2293"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}